Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moCompany
Hetero
India - Hyderabad
LEVOFLOXACIN (levofloxacin) by Hetero is [see microbiology ( )] . Approved for plague, including pneumonic, septicemic plague and 29 more indications. First approved in 2011.
Drug data last refreshed 20h ago
[see Microbiology ( )] .
Worked on LEVOFLOXACIN at Hetero? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study of Levofloxacin Ocular Implant in Patients Undergoing Routine Bilateral Cataract Surgery
Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB
Levofloxacin Ocular Implant for Ocular Surgery
The Clinical Safety of Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%
The Pharmacokinetics of Topical Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo